VRNI
MCID: VTR013
MIFTS: 61

Vitreoretinopathy, Neovascular Inflammatory (VRNI)

Categories: Eye diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Vitreoretinopathy, Neovascular Inflammatory

MalaCards integrated aliases for Vitreoretinopathy, Neovascular Inflammatory:

Name: Vitreoretinopathy, Neovascular Inflammatory 58 76 30 13 6 41
Proliferative Vitreoretinopathy 58 12 76 15 17 74
Adniv 58 60 76
Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy 60 38
Vrni 58 76
Pvr 58 76
Vitreoretinopathy, Neovascular Inflammatory, Autosomal Dominant; Adniv 58
Vitreoretinopathy, Neovascular Inflammatory, Autosomal Dominant 58
Neovascular Inflammatory Vitreoretinopathy Autosomal Dominant 76
Proliferative Vitreoretinopathy; Pvr 58
Vitreoretinopathy, Proliferative 45
Proliferative Vitreo-Retinopathy 74
Vitreoretinopathy Proliferative 56
Retinitis Proliferans 12

Characteristics:

Orphanet epidemiological data:

60
autosomal dominant neovascular inflammatory vitreoretinopathy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: All ages;

OMIM:

58
Inheritance:
autosomal dominant (11q13)


HPO:

33
vitreoretinopathy, neovascular inflammatory:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 60  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:9719
OMIM 58 193235
KEGG 38 H01798
MeSH 45 D018630
ICD10 via Orphanet 35 H35.2
Orphanet 60 ORPHA329211

Summaries for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot : 76 Vitreoretinopathy, neovascular inflammatory: An autoimmune condition of the eye that sequentially mimics uveitis, retinitis pigmentosa, and proliferative diabetic retinopathy as it progresses to complete blindness. Patients present during the second or third decade of life with posterior uveitis and reduction of the electroretinogram b-wave. They become more symptomatic when cataracts, cystoid macular edema, and disk edema diminish visual acuity during the second stage. Severe vision loss begins during the third stage when proliferative retinal neovascularization and epiretinal membranes appear. There is an ongoing pigmentary retinal degeneration and peripheral visual field loss during all stages. In the fourth stage, proliferative vitreoretinopathy causes tractional retinal detachments at the macula and vitreous base. The fifth or end-stage disease is marked by phthisis.

MalaCards based summary : Vitreoretinopathy, Neovascular Inflammatory, also known as proliferative vitreoretinopathy, is related to uveitis and macular retinal edema. An important gene associated with Vitreoretinopathy, Neovascular Inflammatory is CAPN5 (Calpain 5), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Triamcinolone and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are blindness and abnormal electroretinogram

OMIM : 58 Autosomal dominant neovascular inflammatory vitreoretinopathy is a blinding disorder that shares some clinical features with retinitis pigmentosa (see 268000), uveitis, and proliferative diabetic retinopathy (see 603933). Features include prominent ocular inflammation; vascular dropout, large spots of hyperpigmentation, and neovascularization of the peripheral and posterior retina; vitreous hemorrhage; and retinal detachment (summary by Sheffield et al., 1992). (193235)

Related Diseases for Vitreoretinopathy, Neovascular Inflammatory

Diseases related to Vitreoretinopathy, Neovascular Inflammatory via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Related Disease Score Top Affiliating Genes
1 uveitis 30.3 TGFB2 CCL2 CAPN5
2 macular retinal edema 30.1 CCL2 CAPN5
3 macular holes 29.9 TGFB2 CCL2 ADM
4 microvascular complications of diabetes 1 29.4 VTN TIMP1 TGFB2 HGF GFAP FGF2
5 poliomyelitis 11.3
6 paralytic poliomyelitis 11.2
7 cleft palate, isolated 11.1
8 cleft lip/palate-ectodermal dysplasia syndrome 11.1
9 female stress incontinence 11.1
10 agraphia 11.1
11 enterocele 11.1
12 prolapse of female genital organ 11.1
13 basilar artery insufficiency 11.1
14 ovarian cystic teratoma 11.1
15 mature teratoma of the ovary 11.1
16 urethral diverticulum 11.1
17 microvascular complications of diabetes 5 10.7
18 microvascular complications of diabetes 2 10.6
19 retinal detachment 10.4
20 preretinal fibrosis 10.3 TGFB2 GFAP
21 retinitis 10.3
22 breast cancer 10.3
23 cornea cancer 10.3 GFAP FGF2
24 stiff skin syndrome 10.2 TGFB2 TGFB1
25 cataract 10.2
26 laryngitis 10.2 TGFB1 FGF2
27 tuberculoid leprosy 10.2 TGFB2 TGFB1
28 diabetic foot ulcers 10.2 TGFB1 CCL2
29 chronic myocardial ischemia 10.2 HGF FGF2
30 coats disease 10.1
31 neuroma 10.1 TGFB1 GFAP FGF2
32 telangiectasis 10.1
33 tuberous sclerosis 10.1
34 eales disease 10.1
35 peyronie's disease 10.1 TGFB2 TGFB1 CCL2
36 ascending cholangitis 10.0 TGFB1 CCL2
37 nonspecific interstitial pneumonia 10.0 TGFB1 FGF2 CCL2
38 tetralogy of fallot 10.0
39 human immunodeficiency virus type 1 10.0
40 thrombosis 10.0
41 portal vein thrombosis 10.0
42 cleft lip 10.0
43 cleft lip/palate 10.0
44 hydrocephalus 10.0 TGFB2 TGFB1 GFAP
45 macular dystrophy, dominant cystoid 10.0
46 retinoblastoma 10.0
47 chlamydia 10.0
48 retinal disease 10.0
49 retinal degeneration 10.0
50 leishmaniasis 10.0

Graphical network of the top 20 diseases related to Vitreoretinopathy, Neovascular Inflammatory:



Diseases related to Vitreoretinopathy, Neovascular Inflammatory

Symptoms & Phenotypes for Vitreoretinopathy, Neovascular Inflammatory

Human phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

33 (show all 9)
# Description HPO Frequency HPO Source Accession
1 blindness 33 HP:0000618
2 abnormal electroretinogram 33 HP:0000512
3 retinal detachment 33 HP:0000541
4 uveitis 33 HP:0000554
5 vitreoretinopathy 33 HP:0007773
6 vitreous hemorrhage 33 HP:0007902
7 large hyperpigmented retinal spots 33 HP:0007658
8 posterior retinal neovascularization 33 HP:0007778
9 peripheral retinal neovascularization 33 HP:0030667

Symptoms via clinical synopsis from OMIM:

58
Eyes:
blindness
retinal detachment
vitreous hemorrhage
neovascular inflammatory vitreoretinopathy
prominent ocular inflammation
more
Lab:
distinct b-wave abnormality on electrooculography

Clinical features from OMIM:

193235

GenomeRNAi Phenotypes related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

27 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 9.44 TGFB2
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.44 TGFB2
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-184 9.44 CAPN5
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 9.44 TGFB2
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.44 CAPN5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.44 TGFB2
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.44 TGFB2
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.44 CAPN5 TGFB1 TGFB2
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.44 TGFB2
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.44 CAPN5
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-98 9.44 CAPN5

MGI Mouse Phenotypes related to Vitreoretinopathy, Neovascular Inflammatory:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 ADM FGF1 FGF2 FN1 HGF SPARC
2 cardiovascular system MP:0005385 9.92 ADM FGF2 FN1 GFAP HGF TGFB1
3 homeostasis/metabolism MP:0005376 9.85 ADM FGF1 FGF2 FN1 GFAP SPARC
4 immune system MP:0005387 9.61 ADM CAPN5 CCL2 FN1 GFAP SPARC
5 muscle MP:0005369 9.1 ADM FGF2 FN1 GFAP TGFB1 TGFB2

Drugs & Therapeutics for Vitreoretinopathy, Neovascular Inflammatory

Drugs for Vitreoretinopathy, Neovascular Inflammatory (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
2
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
3
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
4 triamcinolone acetonide Phase 4,Phase 3
5 glucocorticoids Phase 4,Phase 3,Early Phase 1
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Early Phase 1
7 Hormone Antagonists Phase 4,Phase 3,Early Phase 1
8 Immunologic Factors Phase 4,Phase 3
9 Triamcinolone diacetate Phase 4,Phase 3
10 Anti-Inflammatory Agents Phase 4,Phase 3
11 Peripheral Nervous System Agents Phase 4,Phase 3
12 Triamcinolone hexacetonide Phase 4,Phase 3
13 Hormones Phase 4,Phase 3,Early Phase 1
14 Immunosuppressive Agents Phase 4,Phase 3
15 Dermatologic Agents Phase 4
16 Central Nervous System Depressants Phase 4,Not Applicable
17 Anesthetics Phase 4
18 Anesthetics, Local Phase 4
19
Colchicine Approved Phase 3 64-86-8 6167 2833
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
22
Dalteparin Approved Phase 3 9005-49-6
23
Fluorouracil Approved Phase 3 51-21-8 3385
24
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
25
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
26
Vitamin C Approved, Nutraceutical Phase 3 50-81-7 5785 54670067
27 Antimitotic Agents Phase 3
28 Antirheumatic Agents Phase 3
29 Gastrointestinal Agents Phase 3
30 Antineoplastic Agents, Hormonal Phase 3
31 Antiemetics Phase 3
32 Anticoagulants Phase 3
33 Calcium, Dietary Phase 3
34 Heparin, Low-Molecular-Weight Phase 3
35
protease inhibitors Phase 3
36 Autonomic Agents Phase 3
37 BB 1101 Phase 3
38 Fibrinolytic Agents Phase 3
39 HIV Protease Inhibitors Phase 3
40 calcium heparin Phase 3
41 Antimetabolites Phase 3
42 Antimetabolites, Antineoplastic Phase 3
43 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
44
Bevacizumab Approved, Investigational Phase 2,Not Applicable 216974-75-3
45 Angiogenesis Modulating Agents Phase 2,Not Applicable
46 Angiogenesis Inhibitors Phase 2,Not Applicable
47 Antineoplastic Agents, Immunological Phase 2,Not Applicable
48
Temazepam Approved, Investigational Not Applicable 846-50-4 5391
49
Epinephrine Approved, Vet_approved Early Phase 1 51-43-4 5816
50
Racepinephrine Approved Early Phase 1 329-65-7 838

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Isotretinoin for Proliferative Vitreoretinopathy Completed NCT01445028 Phase 4 Isotretinoin
2 Postoperative Pain Control Following Vitreoretinal Surgery Completed NCT01995045 Phase 4 Triamcinolone;Bupivicaine Hydrochloride
3 Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment Unknown status NCT00370201 Phase 3 colchicine
4 Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Unknown status NCT00370760 Phase 3 oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
5 Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. Unknown status NCT02834559 Phase 3 5-fluorouracil and low molecular weight heparin;Placebo
6 The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR Unknown status NCT00371020 Phase 3 low molecular weight heparin, 5-FU
7 Comparison High-Density Silicone Oils in Retinal Detachment Unknown status NCT00403702 Phase 2, Phase 3 Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
8 Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial Unknown status NCT00370279 Phase 3
9 Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy Completed NCT00373282 Phase 3 Triamcinolone acetonide
10 The Silicone Study Completed NCT00000140 Phase 3 Perfluoropropane;Sulfur Hexafluoride;Silicone Oil
11 Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study Recruiting NCT02873026 Phase 3 Triamcinolone Acetonide
12 Dacorin for Proliferative Vitreoretinopathy Completed NCT02865031 Phase 1, Phase 2 Decorin
13 Stem Cell Therapy for Outer Retinal Degenerations Recruiting NCT02903576 Phase 1, Phase 2
14 Bevacizumab Against Recurrent Retinal Detachment Active, not recruiting NCT02192970 Phase 2 Bevacizumab
15 Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery. Unknown status NCT01959568 Not Applicable
16 Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel Unknown status NCT00892619 Not Applicable
17 Optical Coherence Tomography - Rescan During Dissection of Macular Membranes Unknown status NCT02748421 Not Applicable
18 Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy Completed NCT03208205
19 Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments Completed NCT01255293 Not Applicable
20 Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment. Completed NCT01860586 Not Applicable Bevacizumab
21 23 Gauge and 20 Gauge Vitrectomy for Rhegmatogenous Retinal Detachments Completed NCT01716507 Not Applicable
22 Adaptive Optics in PVR Recruiting NCT03551574
23 Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment Active, not recruiting NCT03542162 Not Applicable
24 Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) Not yet recruiting NCT03727776 Early Phase 1 Adrenocorticotropic Hormone
25 Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria Not yet recruiting NCT02871531 Not Applicable

Search NIH Clinical Center for Vitreoretinopathy, Neovascular Inflammatory

Cochrane evidence based reviews: vitreoretinopathy, proliferative

Genetic Tests for Vitreoretinopathy, Neovascular Inflammatory

Genetic tests related to Vitreoretinopathy, Neovascular Inflammatory:

# Genetic test Affiliating Genes
1 Vitreoretinopathy, Neovascular Inflammatory 30 CAPN5

Anatomical Context for Vitreoretinopathy, Neovascular Inflammatory

MalaCards organs/tissues related to Vitreoretinopathy, Neovascular Inflammatory:

42
Eye, Retina, Endothelial, Monocytes, Placenta

Publications for Vitreoretinopathy, Neovascular Inflammatory

Articles related to Vitreoretinopathy, Neovascular Inflammatory:

(show top 50) (show all 695)
# Title Authors Year
1
SINGLE NUCLEOTIDE POLYMORPHISMS IN RETINAL DETACHMENT PATIENTS WITH AND WITHOUT PROLIFERATIVE VITREORETINOPATHY. ( 30807515 )
2019
2
Safety, pharmacokinetics, and prevention effect of intraocular crocetin in proliferative vitreoretinopathy. ( 30551371 )
2019
3
Proliferative Vitreoretinopathy: A Review. ( 30585928 )
2019
4
Proteomic evidence that ABCA4 is vital for traumatic proliferative vitreoretinopathy formation and development. ( 30738069 )
2019
5
Clinicopathologic Correlation of a Subretinal Proliferative Vitreoretinopathy Band in a Patient with Chronic Recurrent Retinal Detachment. ( 29928223 )
2018
6
Personalized Proteomics in Proliferative Vitreoretinopathy Implicate Hematopoietic Cell Recruitment and mTOR as a Therapeutic Target. ( 29246578 )
2018
7
ASSOCIATION STUDY BETWEEN POLYMORPHISMS OF THE p53 AND LYMPHOTOXIN ALPHA (LTA) GENES AND THE RISK OF PROLIFERATIVE VITREORETINOPATHY/RETINAL DETACHMENT IN A MEXICAN POPULATION. ( 28106707 )
2018
8
Anterior proliferative vitreoretinopathy in a patient with Coats disease. ( 29487831 )
2018
9
Postoperative aqueous humour flare as a surrogate marker for proliferative vitreoretinopathy development. ( 29068530 )
2018
10
PREDICTIVE FACTORS FOR PROLIFERATIVE VITREORETINOPATHY FORMATION AFTER UNCOMPLICATED PRIMARY RETINAL DETACHMENT REPAIR. ( 29787465 )
2018
11
Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial. ( 30012187 )
2018
12
Internal Limiting Membrane Peeling in Macula-Off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy. ( 30190076 )
2018
13
Internal Limiting Membrane Peeling in Macula-off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy. ( 30274783 )
2018
14
Correlation of transforming growth factor β-1 vitreous levels with clinical severity of proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. ( 30309666 )
2018
15
Outcomes of Retinectomy in Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy. ( 30369377 )
2018
16
NOVEL ENDOSCOPE-ASSISTED VITREOUS SURGERY COMBINED WITH ATMOSPHERIC ENDOSCOPIC TECHNIQUE AND/OR SUBRETINAL ENDOSCOPIC TECHNIQUE FOR RHEGMATOGENOUS RETINAL DETACHMENT WITH GRADE C PROLIFERATIVE VITREORETINOPATHY. ( 29528982 )
2018
17
Levels of Anti-Retinal Antibodies in Retinal Detachment and Proliferative Vitreoretinopathy. ( 29547015 )
2018
18
Internal Limiting Membrane Peeling in Macula-off Retinal Detachment Complicated by Grade B Proliferative Vitreoretinopathy. ( 29621507 )
2018
19
EFFICACY OF INTRAVITREAL INJECTION OF BEVACIZUMAB IN VITRECTOMY FOR PATIENTS WITH PROLIFERATIVE VITREORETINOPATHY RETINAL DETACHMENT: A Meta-analysis of Prospective Studies. ( 28272285 )
2018
20
Prophylactic chorioretinectomy for eye injuries with high proliferative-vitreoretinopathy risk. ( 28635048 )
2018
21
Nonsteroid anti-inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one. ( 28639085 )
2018
22
Effect of Biodegradable Scleral Plugs Containing Curcumin on Proliferative Vitreoretinopathy. ( 28942445 )
2018
23
Evaluation of the Effect of Everolimus on Retinal Pigment Epithelial Cells and Experimental Proliferative Vitreoretinopathy. ( 29182404 )
2018
24
OUTCOMES OF REPEAT PARS PLANA VITRECTOMY AFTER FAILED SURGERY FOR PROLIFERATIVE VITREORETINOPATHY. ( 29232332 )
2018
25
Twenty five-gauge endoscopic vitrectomy for proliferative vitreoretinopathy with severe corneal opacity. ( 29460017 )
2018
26
New model of proliferative vitreoretinopathy in rabbit for drug delivery and pharmacodynamic studies. ( 29461171 )
2018
27
Protective Effects of Fucoidan on Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells and Progression of Proliferative Vitreoretinopathy. ( 29698960 )
2018
28
Animal Models of Proliferative Vitreoretinopathy and Their Use in Pharmaceutical Investigations. ( 29723860 )
2018
29
Comparison of SNP Genotypes Related to Proliferative Vitreoretinopathy (PVR) across Slovenian and European Subpopulations. ( 29862067 )
2018
30
Experimental proliferative vitreoretinopathy in rabbits by delivery of bioactive proteins with gelatin microspheres. ( 29906511 )
2018
31
Effects of Curcumin on Epidermal Growth Factor in Proliferative Vitreoretinopathy. ( 29975931 )
2018
32
Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study. ( 30128605 )
2018
33
Altered Decorin Biology in Proliferative Vitreoretinopathy: A Mechanistic and Cohort Study. ( 30347087 )
2018
34
Comparison of Surgically Excised Premacular Membranes in Eyes with Macular Pucker and Proliferative Vitreoretinopathy. ( 30373411 )
2018
35
Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial. ( 30381390 )
2018
36
BMP7 antagonizes proliferative vitreoretinopathy through retinal pigment epithelial fibrosis in vivo and in vitro. ( 30383450 )
2018
37
Comprehensive circular RNA profiling of proliferative vitreoretinopathy and its clinical significance. ( 30597308 )
2018
38
The influence of systemic renin-angiotensin-inhibition on ocular cytokines related to proliferative vitreoretinopathy. ( 28600710 )
2017
39
The effects of pleiotrophin in proliferative vitreoretinopathy. ( 28083679 )
2017
40
Outcomes of Vitrectomy in Pediatric Retinal Detachment with Proliferative Vitreoretinopathy. ( 28840039 )
2017
41
[The significance of fibroblasts in experimental modeling of proliferative vitreoretinopathy]. ( 29165406 )
2017
42
Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative Vitreoretinopathy. ( 29049737 )
2017
43
Biological Involvement of MicroRNAs in Proliferative Vitreoretinopathy. ( 28706757 )
2017
44
Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial. ( 28237428 )
2017
45
SUBRETINAL TRANSPLANTATION OF AN AUTOLOGOUS RETINAL FREE FLAP FOR CHRONIC RETINAL DETACHMENT WITH PROLIFERATIVE VITREORETINOPATHY WITH AND WITHOUT MACULAR HOLE. ( 29293208 )
2017
46
Substance P prevents development of proliferative vitreoretinopathy in mice by modulating TNF-I+. ( 29296073 )
2017
47
STAINING-ASSISTED REMOVAL OF SILICONE OIL FOR THE IDENTIFICATION OF SUBCLINICAL PROLIFERATIVE VITREORETINOPATHY. ( 28045788 )
2017
48
Preoperative aqueous humour flare values do not predict proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. ( 28077370 )
2017
49
Proliferative Vitreoretinopathy in Treated Retinoblastoma. ( 28435935 )
2017
50
Notch signaling modulates proliferative vitreoretinopathy via regulating retinal pigment epithelial-to-mesenchymal transition. ( 27600720 )
2017

Variations for Vitreoretinopathy, Neovascular Inflammatory

UniProtKB/Swiss-Prot genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

76
# Symbol AA change Variation ID SNP ID
1 CAPN5 p.Arg243Leu VAR_069277 rs397514601
2 CAPN5 p.Leu244Pro VAR_069278 rs397514602

ClinVar genetic disease variations for Vitreoretinopathy, Neovascular Inflammatory:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CAPN5 NM_004055.4(CAPN5): c.728G> T (p.Arg243Leu) single nucleotide variant Pathogenic rs397514601 GRCh37 Chromosome 11, 76826469: 76826469
2 CAPN5 NM_004055.4(CAPN5): c.728G> T (p.Arg243Leu) single nucleotide variant Pathogenic rs397514601 GRCh38 Chromosome 11, 77115423: 77115423
3 CAPN5 NM_004055.4(CAPN5): c.731T> C (p.Leu244Pro) single nucleotide variant Pathogenic rs397514602 GRCh37 Chromosome 11, 76826472: 76826472
4 CAPN5 NM_004055.4(CAPN5): c.731T> C (p.Leu244Pro) single nucleotide variant Pathogenic rs397514602 GRCh38 Chromosome 11, 77115426: 77115426
5 CAPN5 NM_004055.4(CAPN5): c.865C> T (p.Arg289Trp) single nucleotide variant Pathogenic rs886041303 GRCh38 Chromosome 11, 77115560: 77115560
6 CAPN5 NM_004055.4(CAPN5): c.865C> T (p.Arg289Trp) single nucleotide variant Pathogenic rs886041303 GRCh37 Chromosome 11, 76826606: 76826606
7 CAPN5 NM_004055.4(CAPN5): c.1894C> A (p.Leu632Ile) single nucleotide variant Likely benign rs111264315 GRCh37 Chromosome 11, 76834887: 76834887
8 CAPN5 NM_004055.4(CAPN5): c.1894C> A (p.Leu632Ile) single nucleotide variant Likely benign rs111264315 GRCh38 Chromosome 11, 77123841: 77123841

Expression for Vitreoretinopathy, Neovascular Inflammatory

Search GEO for disease gene expression data for Vitreoretinopathy, Neovascular Inflammatory.

Pathways for Vitreoretinopathy, Neovascular Inflammatory

Pathways related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 CAPN5 CCL2 FGF1 FGF2 FN1 GFAP
2
Show member pathways
13.45 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
3
Show member pathways
13.33 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
4
Show member pathways
13.31 CAPN5 CCL2 FN1 TGFB1 TGFB2 VTN
5
Show member pathways
13.28 CCL2 FGF1 FGF2 FN1 HGF TGFB1
6
Show member pathways
13.24 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
7
Show member pathways
13.23 FN1 HGF SPARC TGFB1 TGFB2 TIMP1
8
Show member pathways
13.23 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
9
Show member pathways
13.19 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
10
Show member pathways
13 FGF1 FGF2 FN1 HGF TGFB1 TGFB2
11
Show member pathways
12.98 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
12
Show member pathways
12.91 FGF1 FGF2 FN1 HGF VTN
13 12.79 FGF1 FGF2 FN1 HGF TGFB1 TGFB2
14 12.7 FGF1 FGF2 HGF TGFB1 TGFB2
15
Show member pathways
12.7 FGF1 FGF2 HGF TGFB1 TGFB2
16
Show member pathways
12.64 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
17
Show member pathways
12.58 CAPN5 FGF2 FN1 SPARC TGFB1 TGFB2
18
Show member pathways
12.52 CCL2 FGF2 FN1 TIMP1
19
Show member pathways
12.35 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
20
Show member pathways
12.2 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
21 12.18 FGF2 FN1 HGF TGFB1 TGFB2 VTN
22 12.07 FGF1 TGFB1 TGFB2
23 12.04 HGF TGFB1 TGFB2
24 11.99 FGF2 HGF TGFB1
25 11.94 CCL2 GFAP TGFB1
26 11.93 FN1 SPARC TGFB1 VTN
27
Show member pathways
11.93 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
28 11.89 CCL2 FN1 TGFB1 TGFB2
29 11.83 FN1 TGFB1 TGFB2
30 11.8 CCL2 TGFB1 TGFB2
31 11.79 CCL2 FGF2 FN1 HGF TGFB1 TIMP1
32
Show member pathways
11.69 TGFB1 TGFB2 VTN
33 11.68 CCL2 TGFB1 TGFB2
34 11.64 FGF2 TGFB1 TGFB2
35 11.62 FN1 SPARC TIMP1 VTN
36 11.6 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1
37 11.58 SPARC TGFB1 TGFB2 VTN
38 11.49 FGF2 FN1 TGFB1 TGFB2
39 11.47 FGF2 FN1 VTN
40 11.47 CCL2 HGF TGFB1 TGFB2
41 11.44 FGF1 FGF2 HGF TGFB1
42 11.26 HGF TGFB1 TGFB2
43 11.23 CCL2 FGF1 FGF2 HGF TGFB1 TIMP1
44 11.12 FGF2 TGFB1
45 11.12 CCL2 FGF1 FGF2 HGF TGFB1 TGFB2
46 11.11 CCL2 TIMP1
47 11.02 FN1 TGFB1
48 10.97 CCL2 TIMP1
49 10.95 FN1 TGFB1
50 10.92 HGF TGFB1

GO Terms for Vitreoretinopathy, Neovascular Inflammatory

Cellular components related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.9 ADM CCL2 FGF1 FGF2 FN1 HGF
2 collagen-containing extracellular matrix GO:0062023 9.77 FN1 SPARC TGFB1 TGFB2 VTN
3 extracellular matrix GO:0031012 9.73 FGF1 FN1 SPARC TGFB1 TIMP1 VTN
4 extracellular space GO:0005615 9.7 ADM CCL2 FGF1 FGF2 FN1 HGF
5 basement membrane GO:0005604 9.62 FN1 SPARC TIMP1 VTN
6 blood microparticle GO:0072562 9.58 FN1 TGFB1 VTN
7 platelet alpha granule lumen GO:0031093 9.1 FN1 HGF SPARC TGFB1 TGFB2 TIMP1

Biological processes related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.93 FGF1 HGF TGFB1 TGFB2 VTN
2 heart development GO:0007507 9.91 ADM SPARC TGFB1 TGFB2
3 positive regulation of cell proliferation GO:0008284 9.91 ADM FGF1 FGF2 FN1 TGFB1 TGFB2
4 angiogenesis GO:0001525 9.88 CCL2 FGF1 FGF2 FN1 TGFB2
5 response to hypoxia GO:0001666 9.85 ADM TGFB1 TGFB2
6 positive regulation of protein kinase B signaling GO:0051897 9.85 FGF1 FGF2 HGF TGFB1
7 MAPK cascade GO:0000165 9.85 CCL2 FGF1 FGF2 HGF TGFB1
8 activation of MAPK activity GO:0000187 9.84 FGF1 FGF2 HGF
9 phosphatidylinositol phosphorylation GO:0046854 9.83 FGF1 FGF2 HGF
10 extracellular matrix organization GO:0030198 9.83 FGF2 FN1 GFAP SPARC VTN
11 response to organic substance GO:0010033 9.81 ADM TGFB1 TIMP1
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 HGF TGFB1 VTN
13 positive regulation of angiogenesis GO:0045766 9.8 ADM FGF1 FGF2 HGF
14 cytokine-mediated signaling pathway GO:0019221 9.8 CCL2 FGF2 FN1 HGF TGFB1 TIMP1
15 neural tube closure GO:0001843 9.79 ADM TGFB1 TGFB2
16 positive regulation of MAP kinase activity GO:0043406 9.77 FGF1 FGF2 TGFB1
17 inner ear development GO:0048839 9.74 SPARC TGFB1 TGFB2
18 animal organ regeneration GO:0031100 9.73 ADM HGF TGFB1
19 positive regulation of cell division GO:0051781 9.71 FGF1 FGF2 TGFB1 TGFB2
20 epithelial to mesenchymal transition GO:0001837 9.69 HGF TGFB1 TGFB2
21 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.68 TGFB1 TGFB2
22 positive regulation of sprouting angiogenesis GO:1903672 9.67 FGF1 FGF2
23 cell-cell junction organization GO:0045216 9.67 TGFB1 TGFB2
24 hyaluronan catabolic process GO:0030214 9.66 FGF2 TGFB1
25 positive regulation of DNA biosynthetic process GO:2000573 9.65 FGF2 HGF
26 negative regulation of immune response GO:0050777 9.65 TGFB1 TGFB2
27 response to wounding GO:0009611 9.65 ADM FN1 GFAP TGFB1 TGFB2
28 pathway-restricted SMAD protein phosphorylation GO:0060389 9.64 TGFB1 TGFB2
29 cell activation GO:0001775 9.64 TGFB1 TIMP1
30 platelet degranulation GO:0002576 9.63 FN1 HGF SPARC TGFB1 TGFB2 TIMP1
31 salivary gland morphogenesis GO:0007435 9.62 TGFB1 TGFB2
32 heart valve morphogenesis GO:0003179 9.61 TGFB1 TGFB2
33 connective tissue replacement involved in inflammatory response wound healing GO:0002248 9.59 TGFB1 TIMP1
34 negative regulation of macrophage cytokine production GO:0010936 9.58 TGFB1 TGFB2
35 neuron projection regeneration GO:0031102 9.58 ADM GFAP
36 regulation of signaling receptor activity GO:0010469 9.56 ADM CCL2 FGF1 FGF2 HGF TGFB1
37 regulation of endothelial cell chemotaxis to fibroblast growth factor GO:2000544 9.52 FGF1 FGF2
38 wound healing GO:0042060 9.1 FGF2 FN1 SPARC TGFB1 TGFB2 TIMP1

Molecular functions related to Vitreoretinopathy, Neovascular Inflammatory according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.78 ADM CCL2 FN1 TGFB2
2 protein tyrosine kinase activity GO:0004713 9.69 FGF1 FGF2 HGF
3 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.63 FGF1 FGF2 HGF
4 heparin binding GO:0008201 9.62 FGF1 FGF2 FN1 VTN
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.58 FGF1 FGF2 HGF
6 cytokine activity GO:0005125 9.55 CCL2 FGF2 TGFB1 TGFB2 TIMP1
7 collagen binding GO:0005518 9.54 FN1 SPARC VTN
8 fibroblast growth factor receptor binding GO:0005104 9.49 FGF1 FGF2
9 type II transforming growth factor beta receptor binding GO:0005114 9.43 TGFB1 TGFB2
10 integrin binding GO:0005178 9.35 FGF1 FGF2 FN1 GFAP VTN
11 type III transforming growth factor beta receptor binding GO:0034714 9.26 TGFB1 TGFB2
12 growth factor activity GO:0008083 9.1 FGF1 FGF2 HGF TGFB1 TGFB2 TIMP1

Sources for Vitreoretinopathy, Neovascular Inflammatory

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....